Pharvaris Presents Deucrictibant Clinical Data And Real-World HAE Treatment Satisfaction Data At ACAAI 2023 Annual Scientific Meeting
Portfolio Pulse from Benzinga Newsdesk
Pharvaris (NASDAQ:PHVS) announced the presentation of two ePosters at the ACAAI 2023 Annual Scientific Meeting. The posters will present clinical data on Deucrictibant, a drug being developed to treat hereditary angioedema (HAE), and real-world HAE treatment satisfaction data. The phase 2 RAPIDe-1 trial showed that PHVS416 (immediate-release deucrictibant capsules) reduced time to symptom relief and use of rescue medication. The company aims to develop this formulation to provide rapid and reliable symptom relief in an easy-to-administer, small oral dosage form.
November 09, 2023 | 4:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pharvaris's presentation of positive clinical data on Deucrictibant and real-world HAE treatment satisfaction data at ACAAI 2023 could potentially boost investor confidence in the company's ongoing development of PHVS416 for the on-demand treatment of HAE.
The positive clinical data presented by Pharvaris at the ACAAI 2023 Annual Scientific Meeting indicates that the company's PHVS416 drug has potential in treating HAE. This could potentially boost investor confidence in the company's ongoing development of the drug, leading to a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100